Alkem Laboratories Limited has incorporated a wholly owned subsidiary in Dubai, UAE, named Alkem Pharma Trading FZCO, with the specific purpose of expanding pharmaceutical exports to African, South East Asian, and other non-UAE markets, the Mumbai-based drug maker disclosed to BSE and NSE on April 13, 2026 under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations.
The new entity was incorporated on March 27, 2026 in the Dubai Airport Free Zone, with the Certificate of Formation received from the Dubai Airport Free Zone Authority on April 13, 2026 — the same day as the regulatory disclosure. The authorised and subscribed share capital of Alkem Pharma Trading FZCO stands at AED 36,70,000, divided into 3,67,000 equity shares of AED 10 each, with Alkem Laboratories holding 100% of the equity through a cash subscription of AED 3,670,000.
The Dubai Airport Free Zone is a strategically significant choice of domicile for a pharmaceutical export hub. The free zone offers zero corporate tax, full foreign ownership, no import or re-export duties, and direct connectivity to one of the world’s busiest air cargo hubs — advantages that make it one of the most cost-effective and logistically efficient bases from which to manage pharmaceutical distribution across the Middle East, Africa, and South East Asia. Indian pharmaceutical companies have increasingly used Dubai free zones as regional trading and distribution hubs given the city’s position at the geographic crossroads of the markets Alkem is explicitly targeting.
The Africa angle is particularly relevant in the current global context. African pharmaceutical markets have been among the fastest-growing destinations for Indian generic drug exports over the past decade, driven by expanding healthcare infrastructure, increasing government health spending, disease burden requiring affordable generic medicines, and the competitive pricing advantage that Indian manufacturers hold relative to branded Western alternatives. Alkem has an established domestic generics franchise in India and the UAE subsidiary provides the regulatory and logistical platform to systematically expand that distribution into African markets where direct access from India can be commercially and operationally complex.
South East Asia similarly represents a substantial opportunity for Indian generic pharmaceutical companies. Markets including Vietnam, Indonesia, Philippines, Thailand, and Myanmar have significant and growing demand for affordable medicines across therapeutic categories where Alkem has established product portfolios. A UAE-based trading entity with free zone advantages removes several layers of commercial friction in serving these markets through a hub-and-spoke distribution model.
The incorporation of Alkem Pharma Trading FZCO at this specific moment — with the Iran war having disrupted Gulf region logistics and the Strait of Hormuz crisis affecting regional supply chains — is either coincidental timing or reflects Alkem’s assessment that establishing a permanent trading infrastructure in the UAE now positions the company to benefit from regional market normalisation once the current disruption resolves. The Dubai Airport Free Zone’s air cargo orientation means the subsidiary is less dependent on the maritime supply chain disruptions that have characterised the Hormuz crisis than a sea-freight-dependent distribution model would be.
Alkem Laboratories is listed on BSE under scrip code 539523 and on NSE under the symbol ALKEM.
Disclaimer: This article is based on official company disclosures filed with BSE and NSE on April 13, 2026. Business Upturn is not responsible for any investment decisions made based on this article.